Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21

September 15, 2021

New LUMAKRAS™ (sotorasib) Post-Hoc Analysis Shows Intracranial Disease Control was Achieved in a Subset of Patients With Previously Treated Evaluable Stable Brain Metastases
Additional Featured Research Includes Exploratory Analysis of Potential Genomic Determinants of LUMAKRAS Response
THOUSAND OAKS, Calif. , Sept. 8, 2021 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced results from two analyses of the Phase 2 CodeBreaK 100 clinical trial evaluating LUMAKRAS™ (sotorasib), the first and only KRAS G12C inhibitor approved in the U.S., in the treatment of previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). These new analyses, respectively, provide encouraging evidence …

Read the source article at Yahoo Finance
2021-09-08 20:00:00

Share This Story!